Research Analysts Issue Forecasts for Nuvation Bio Inc.’s Q2 2025 Earnings (NYSE:NUVB)

Nuvation Bio Inc. (NYSE:NUVB) – Equities researchers at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Nuvation Bio in a research note issued to investors on Wednesday, May 22nd. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.10) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q3 2025 earnings at ($0.11) EPS.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04.

NUVB has been the subject of a number of other reports. BTIG Research upgraded shares of Nuvation Bio from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Tuesday, March 26th. Royal Bank of Canada raised their price objective on shares of Nuvation Bio from $4.00 to $5.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Jefferies Financial Group upgraded shares of Nuvation Bio from a “hold” rating to a “buy” rating and raised their price objective for the stock from $1.40 to $10.00 in a research report on Wednesday, March 27th. Finally, Wedbush reiterated an “outperform” rating and set a $5.00 target price on shares of Nuvation Bio in a research report on Friday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $6.60.

Nuvation Bio Stock Performance

NUVB stock opened at $3.09 on Thursday. The stock has a 50-day moving average price of $3.04 and a two-hundred day moving average price of $2.11. The stock has a market cap of $762.52 million, a PE ratio of -9.95 and a beta of 1.42. Nuvation Bio has a 1 year low of $0.95 and a 1 year high of $4.16.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NUVB. Vanguard Group Inc. grew its stake in shares of Nuvation Bio by 3.0% in the first quarter. Vanguard Group Inc. now owns 7,534,148 shares of the company’s stock worth $27,424,000 after purchasing an additional 219,533 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Nuvation Bio by 551.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,354,632 shares of the company’s stock worth $4,932,000 after purchasing an additional 1,146,794 shares during the period. Acadian Asset Management LLC raised its holdings in Nuvation Bio by 81.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,174,464 shares of the company’s stock valued at $4,273,000 after acquiring an additional 528,660 shares during the period. Octagon Capital Advisors LP bought a new stake in Nuvation Bio during the 4th quarter valued at $1,510,000. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Nuvation Bio by 254.1% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 748,793 shares of the company’s stock valued at $2,726,000 after purchasing an additional 537,314 shares in the last quarter. Institutional investors and hedge funds own 61.67% of the company’s stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.